var data={"title":"Breastfeeding infants: Safety of exposure to antipsychotics, lithium, stimulants, and medications for substance use disorders","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Breastfeeding infants: Safety of exposure to antipsychotics, lithium, stimulants, and medications for substance use disorders</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/contributors\" class=\"contributor contributor_credentials\">Mary C Kimmel, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/contributors\" class=\"contributor contributor_credentials\">Samantha Meltzer-Brody, MD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/contributors\" class=\"contributor contributor_credentials\">Peter P Roy-Byrne, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/contributors\" class=\"contributor contributor_credentials\">Charles J Lockwood, MD, MHCM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/contributors\" class=\"contributor contributor_credentials\">David Solomon, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Sep 15, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H86350618\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The benefits of breastfeeding generally appear to outweigh the small risk posed by psychotropic medications that are used to treat postpartum mental disorders in lactating mothers [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/1,2\" class=\"abstract_t\">1,2</a>]. </p><p>This topic reviews the safety of antipsychotics, <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>, and medications for substance use disorders in breastfeeding infants. The safety of anticonvulsants, antidepressants, and benzodiazepines in breastfeeding infants; benefits of lactation; education of parents about breastfeeding; and initiation of breastfeeding are discussed separately, as is choosing a specific drug for treating postpartum psychiatric disorders.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=management-of-epilepsy-and-pregnancy#H15\" class=\"medical medical_review\">&quot;Management of epilepsy and pregnancy&quot;, section on 'Breast feeding'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=safety-of-infant-exposure-to-antidepressants-and-benzodiazepines-through-breastfeeding\" class=\"medical medical_review\">&quot;Safety of infant exposure to antidepressants and benzodiazepines through breastfeeding&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=infant-benefits-of-breastfeeding\" class=\"medical medical_review\">&quot;Infant benefits of breastfeeding&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=maternal-and-economic-benefits-of-breastfeeding\" class=\"medical medical_review\">&quot;Maternal and economic benefits of breastfeeding&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=breastfeeding-parental-education-and-support\" class=\"medical medical_review\">&quot;Breastfeeding: Parental education and support&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=initiation-of-breastfeeding\" class=\"medical medical_review\">&quot;Initiation of breastfeeding&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=severe-postpartum-unipolar-major-depression-treatment\" class=\"medical medical_review\">&quot;Severe postpartum unipolar major depression: Treatment&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=bipolar-disorder-in-postpartum-women-treatment\" class=\"medical medical_review\">&quot;Bipolar disorder in postpartum women: Treatment&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=treatment-of-postpartum-psychosis\" class=\"medical medical_review\">&quot;Treatment of postpartum psychosis&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=obsessive-compulsive-disorder-in-pregnant-and-postpartum-women\" class=\"medical medical_review\">&quot;Obsessive-compulsive disorder in pregnant and postpartum women&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H86353722\"><span class=\"h1\">GENERAL PRINCIPLES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>General principles to bear in mind when choosing a psychotropic drug for postpartum, lactating patients include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients who are successfully treated with drugs during pregnancy should generally not change medications for the purpose of breastfeeding</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients who start pharmacotherapy should be treated with medications that were efficacious in the past</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Avoid polypharmacy if possible </p><p/><p>Additional information about the general principles of using psychotropic drugs in breastfeeding patients is discussed separately, as is choosing specific treatments for postpartum mental disorders. (See <a href=\"topic.htm?path=safety-of-infant-exposure-to-antidepressants-and-benzodiazepines-through-breastfeeding#H2611892\" class=\"medical medical_review\">&quot;Safety of infant exposure to antidepressants and benzodiazepines through breastfeeding&quot;, section on 'General principles'</a> and <a href=\"topic.htm?path=severe-postpartum-unipolar-major-depression-treatment\" class=\"medical medical_review\">&quot;Severe postpartum unipolar major depression: Treatment&quot;</a> and <a href=\"topic.htm?path=bipolar-disorder-in-postpartum-women-treatment\" class=\"medical medical_review\">&quot;Bipolar disorder in postpartum women: Treatment&quot;</a> and <a href=\"topic.htm?path=treatment-of-postpartum-psychosis\" class=\"medical medical_review\">&quot;Treatment of postpartum psychosis&quot;</a> and <a href=\"topic.htm?path=obsessive-compulsive-disorder-in-pregnant-and-postpartum-women\" class=\"medical medical_review\">&quot;Obsessive-compulsive disorder in pregnant and postpartum women&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H29038627\"><span class=\"h2\">Monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pediatricians should assess infant behavior, feeding, alertness, and sleep as well as physically examine infants to establish a baseline [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/3-6\" class=\"abstract_t\">3-6</a>]. Infants exposed to medications via breast milk should then be monitored periodically (eg, monthly) for adverse events such as sleep disturbances, irritability, agitation, excessive crying, or poor weight gain. In addition, infants should be assessed for known drug effects; as an example:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Infants exposed to antipsychotics should be monitored for extrapyramidal symptoms [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/7,8\" class=\"abstract_t\">7,8</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Among infants exposed to <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>, weight should be closely monitored for the first two weeks (eg, postdischarge day one or two and then every three days, until weight gain is appropriate) [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/9\" class=\"abstract_t\">9</a>]. Lactating mothers treated with lithium should be educated about monitoring infant symptoms such as dehydration, feeding problems, or lethargy.</p><p/><p>Serum laboratory tests for infants should also be performed for all indices that can be affected by the medications that the mother is taking (<a href=\"image.htm?imageKey=PSYCH%2F93613\" class=\"graphic graphic_table graphicRef93613 \">table 1</a>); tests should be scheduled at least as often as they are for adults, including those times when maternal drug doses are increased or side effects occur in the infant [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/10\" class=\"abstract_t\">10</a>]. Laboratory monitoring is indicated especially for infants exposed to <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a>, <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>, or <a href=\"topic.htm?path=valproate-drug-information\" class=\"drug drug_general\">valproate</a> [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/11\" class=\"abstract_t\">11</a>].</p><p>If adverse events in infants are suspected, mothers should immediately reduce or suspend breastfeeding [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/4,10\" class=\"abstract_t\">4,10</a>]. This may enable clinicians to determine whether maternal medications caused the adverse events.</p><p class=\"headingAnchor\" id=\"H86350966\"><span class=\"h1\">ANTICONVULSANTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Information about the safety of infant exposure to anticonvulsants through breast milk is discussed separately. (See <a href=\"topic.htm?path=management-of-epilepsy-and-pregnancy#H15\" class=\"medical medical_review\">&quot;Management of epilepsy and pregnancy&quot;, section on 'Breast feeding'</a>.)</p><p class=\"headingAnchor\" id=\"H86349444\"><span class=\"h1\">ANTIPSYCHOTICS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Based upon the limited evidence and our clinical experience, breastfeeding mothers can be encouraged to take antipsychotics if they are indicated and if a discussion of the risk of not treating reveals the possibility of significant negative outcomes for mother and child. The exposure of infants to antipsychotics via human milk generally appears to be low and clinically insignificant [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/12\" class=\"abstract_t\">12</a>]. However, the literature remains scant and more research is needed to make evidence based recommendations [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/7\" class=\"abstract_t\">7</a>].</p><p class=\"headingAnchor\" id=\"H86349450\"><span class=\"h2\">First-generation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Small studies suggest that <a href=\"topic.htm?path=chlorpromazine-drug-information\" class=\"drug drug_general\">chlorpromazine</a> and <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a> may be compatible with breastfeeding.</p><p class=\"headingAnchor\" id=\"H93853802\"><span class=\"h3\">Chlorpromazine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Multiple reviews of studies that examined secretion of <a href=\"topic.htm?path=chlorpromazine-drug-information\" class=\"drug drug_general\">chlorpromazine</a> into breast milk and adverse effects in infants have concluded that chlorpromazine may be compatible with breastfeeding [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/7,13\" class=\"abstract_t\">7,13</a>]. In one review of six observational studies that identified infants (n = 16) whose mothers were treated with chlorpromazine monotherapy, one baby had drowsiness, and no long-term adverse effects were observed among the 16 infants [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/7\" class=\"abstract_t\">7</a>]. Another review concluded that chlorpromazine is excreted in breast milk in small amounts [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/14\" class=\"abstract_t\">14</a>].</p><p class=\"headingAnchor\" id=\"H1441316\"><span class=\"h3\">Haloperidol</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">Haloperidol</a> is a reasonable choice for women who are starting a first-generation antipsychotic while nursing, based upon small observational studies of infants exposed to haloperidol through lactation. The use of haloperidol in breastfeeding women who are treated with a first-generation antipsychotic is consistent with guidance from the National Library of Medicine&rsquo;s <a href=\"http://toxnet.nlm.nih.gov/&amp;token=uFbFTjFpzLQOPfYhN9e/pY7DH5viCPnIbTllaDu+DrTYMoqo9S1gI8gS1H3WjssW&amp;TOPIC_ID=93451\" target=\"_blank\" class=\"external\">LactMed</a> database (United States) [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/15\" class=\"abstract_t\">15</a>]. In addition, multiple reviews of studies that examined secretion of haloperidol into breast milk and adverse effects in infants have concluded that haloperidol may be compatible with breastfeeding [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/7,13\" class=\"abstract_t\">7,13</a>].</p><p>Observational studies have found that most breastfeeding babies are not adversely affected by their mothers&rsquo; use of <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a>:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Multiple case reports (total n = 14 infants) have found no acute adverse effects [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/16-19\" class=\"abstract_t\">16-19</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A prospective observational study found that acute mental and psychomotor development was comparable for babies who were breastfed by mothers taking first-generation antipsychotics (n = 12; 9 of the 12 [75 percent] received <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a>) and for nonbreastfeeding babies whose mothers were taking haloperidol or other drugs (n = 18) [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/17\" class=\"abstract_t\">17</a>].</p><p/><p>In addition, excretion of <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a> in breast milk appears to be small [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/14\" class=\"abstract_t\">14</a>].</p><p class=\"headingAnchor\" id=\"H1441337\"><span class=\"h3\">Other drugs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other first-generation antipsychotics may be compatible with breastfeeding, but the evidence of their safety is sparse. Small observational studies of breastfeeding infants whose mothers were taking chlorprothixene, flupenthixol, <a href=\"topic.htm?path=perphenazine-drug-information\" class=\"drug drug_general\">perphenazine</a>, <a href=\"topic.htm?path=trifluoperazine-drug-information\" class=\"drug drug_general\">trifluoperazine</a>, or <a href=\"topic.htm?path=zuclopenthixol-united-states-not-available-drug-information\" class=\"drug drug_general\">zuclopenthixol</a> (total n = 18 infants) found no acute adverse events [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/7\" class=\"abstract_t\">7</a>]. In addition, a review concluded that perphenazine and trifluoperazine are excreted in breast milk in small amounts [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/14\" class=\"abstract_t\">14</a>].</p><p class=\"headingAnchor\" id=\"H86349456\"><span class=\"h2\">Second-generation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">Olanzapine</a> has been more widely studied in the setting of breastfeeding than other second-generation antipsychotics; these studies suggest that olanzapine may be compatible with breastfeeding [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/20\" class=\"abstract_t\">20</a>]. The next most widely studied drugs appear to be <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> and <a href=\"topic.htm?path=risperidone-drug-information\" class=\"drug drug_general\">risperidone</a>, and the evidence suggest that they may also be compatible with breastfeeding.</p><p class=\"headingAnchor\" id=\"H86353740\"><span class=\"h3\">Aripiprazole</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>It is not clear if <a href=\"topic.htm?path=aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-drug-information\" class=\"drug drug_general\">aripiprazole</a> is compatible with breastfeeding due to the paucity of data [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/20,21\" class=\"abstract_t\">20,21</a>]. One case report described a mother-infant pair in which the mother was prescribed aripiprazole; no acute adverse effects occurred in the infant [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/22\" class=\"abstract_t\">22</a>]. Two separate case reports found that aripiprazole was detectable in breast milk [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/23,24\" class=\"abstract_t\">23,24</a>], whereas one case report found that the drug was not detectable [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/22\" class=\"abstract_t\">22</a>]. One treatment guideline suggests that aripiprazole is a reasonable option for lactating patients because infant exposure is relatively low compared with some other antipsychotics, and adverse effects in nursing children have not been reported [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/12\" class=\"abstract_t\">12</a>].</p><p class=\"headingAnchor\" id=\"H39402073\"><span class=\"h3\">Asenapine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>It is not clear if <a href=\"topic.htm?path=asenapine-drug-information\" class=\"drug drug_general\">asenapine</a> is compatible with breastfeeding because little information is available about its use in lactating women [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/15,20\" class=\"abstract_t\">15,20</a>].</p><p class=\"headingAnchor\" id=\"H86353753\"><span class=\"h3\">Clozapine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We typically encourage women treated with <a href=\"topic.htm?path=clozapine-drug-information\" class=\"drug drug_general\">clozapine</a> to not breastfeed, because infants may be vulnerable to the side effects that occur in adults (eg, hematologic toxicity and seizures) [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/14\" class=\"abstract_t\">14</a>]. In addition, the safety of clozapine has been studied in only a few patients, and the results suggest that the drug is problematic. A review of two observational studies (total n = 5 infants exposed to clozapine) found that one baby suffered agranulocytosis, one baby manifested lethargy, and one had speech delay [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/7\" class=\"abstract_t\">7</a>]. In addition, a case report observed that the accumulation of clozapine in breast milk was high [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/25\" class=\"abstract_t\">25</a>]. Using antipsychotics other than clozapine is consistent with guidelines from the United Kingdom&rsquo;s National Institute for Health and Clinical Excellence [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/6\" class=\"abstract_t\">6</a>] and the British Association for Psychopharmacology [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/14\" class=\"abstract_t\">14</a>], and several reviews have deemed it inadvisable to use clozapine in lactating patients [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/7,12,13,20,21,26\" class=\"abstract_t\">7,12,13,20,21,26</a>].</p><p class=\"headingAnchor\" id=\"H39402100\"><span class=\"h3\">Lurasidone</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>It is not clear if <a href=\"topic.htm?path=lurasidone-drug-information\" class=\"drug drug_general\">lurasidone</a> is compatible with breastfeeding because little information is available about its use in lactating women [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/15,20,21\" class=\"abstract_t\">15,20,21</a>].</p><p class=\"headingAnchor\" id=\"H86353760\"><span class=\"h3\">Olanzapine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">Olanzapine</a> is a reasonable choice for women who require a second-generation antipsychotic while nursing. The use of olanzapine is consistent with guidance from the National Library of Medicine&rsquo;s <a href=\"http://toxnet.nlm.nih.gov/&amp;token=uFbFTjFpzLQOPfYhN9e/pY7DH5viCPnIbTllaDu+DrTYMoqo9S1gI8gS1H3WjssW&amp;TOPIC_ID=93451\" target=\"_blank\" class=\"external\">LactMed</a> database (United States) [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/15\" class=\"abstract_t\">15</a>]. In addition, multiple reviews of observational studies that examined secretion of olanzapine into breast milk and adverse effects in infants have concluded that olanzapine may be compatible with breastfeeding [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/7,12,13,20,21,27\" class=\"abstract_t\">7,12,13,20,21,27</a>].</p><p>Observational studies have found that most breastfeeding babies are not adversely affected by their mothers&rsquo; use of <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a>:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A review of 10 studies (total n = 64 infants exposed to <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a>) found that somnolence was observed in three (5 percent) infants, slow weight gain in two (3 percent), and developmental delay in three (5 percent) [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/7\" class=\"abstract_t\">7</a>]. One of the better studies was a prospective study, which found that adverse events were comparable for breastfeeding infants whose mothers were taking olanzapine <span class=\"nowrap\">(3/22</span> infants, 14 percent), nonbreastfeeding infants of mothers taking olanzapine <span class=\"nowrap\">(1/15,</span> 7 percent), and breastfeeding infants whose mothers were taking a drug known to be safe during lactation <span class=\"nowrap\">(4/51,</span> 8 percent) [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/28\" class=\"abstract_t\">28</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A study examined the manufacturer&rsquo;s safety database, which included all spontaneously reported adverse events in breastfeeding infants (n = 102 exposed infants) [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/29\" class=\"abstract_t\">29</a>]. No adverse events were reported in 82 percent. The most common adverse events associated with exposure were nonspecific, such as somnolence (4 percent of infants), irritability (2 percent), tremor (2 percent), and insomnia (2 percent). </p><p/><p>Several studies of serum assays of infants (total n = 12) exposed to <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a> via breast milk have not detected the drug [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/8,14,30-33\" class=\"abstract_t\">8,14,30-33</a>]. The mechanism may be due to low absorption and distribution of the drug in the large amounts of fat in children [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/8\" class=\"abstract_t\">8</a>]. However, one case report described an infant who had a serum concentration that was approximately 40 percent of the maternal level; subsequent infant serum concentrations were very low or undetectable [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/34\" class=\"abstract_t\">34</a>].</p><p class=\"headingAnchor\" id=\"H536071189\"><span class=\"h3\">Paliperidone</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=paliperidone-drug-information\" class=\"drug drug_general\">Paliperidone</a>, which is the active metabolite of <a href=\"topic.htm?path=risperidone-drug-information\" class=\"drug drug_general\">risperidone</a>, may be compatible with breastfeeding based upon studies of risperidone (see <a href=\"#H86353767\" class=\"local\">'Risperidone'</a> below). In addition, a study of two breastfed infants whose mothers were treated with risperidone found that infant serum concentrations of paliperidone (and risperidone) were not detectable, and there were no adverse effects [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/35\" class=\"abstract_t\">35</a>]. &#160;</p><p class=\"headingAnchor\" id=\"H93853929\"><span class=\"h3\">Quetiapine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most studies suggest that <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> may be compatible with breastfeeding [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/21,27\" class=\"abstract_t\">21,27</a>]. A review of 10 studies (total n = 23 infants exposed to quetiapine) found that one infant became drowsy, which was attributed to the concomitantly prescribed <a href=\"topic.htm?path=mirtazapine-drug-information\" class=\"drug drug_general\">mirtazapine</a>, and two infants (who were also exposed to other concomitantly prescribed medications) manifested slight delays in mental and motor development [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/7\" class=\"abstract_t\">7</a>]. The review concluded that use of quetiapine is compatible with breastfeeding. In addition, one treatment guideline suggests that quetiapine is a reasonable option for lactating patients [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/12\" class=\"abstract_t\">12</a>].</p><p>Infant exposure to <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> through breast milk appears to be low [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/7,12,20\" class=\"abstract_t\">7,12,20</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A case report of a mother-infant pair in which the mother was prescribed <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> found that the infant serum concentration was 6 percent of the maternal concentration (some studies have arbitrarily defined elevated infant levels as those exceeding 10 percent of maternal levels) [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/36\" class=\"abstract_t\">36</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Studies that assayed breast milk concentrations of <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> (n = 7 women) found that quetiapine was not detectable in five patients [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/26,37\" class=\"abstract_t\">26,37</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Studies of breast milk levels (total n = 11 breastfeeding women taking <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a>) concluded that maternal quetiapine therapy was unlikely to pose a significant exposure risk to breastfed infants [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/38-40\" class=\"abstract_t\">38-40</a>] </p><p/><p class=\"headingAnchor\" id=\"H86353767\"><span class=\"h3\">Risperidone</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=risperidone-drug-information\" class=\"drug drug_general\">Risperidone</a> may be compatible with lactation [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/21\" class=\"abstract_t\">21</a>], based upon studies (total n = 6 infants) that found no acute adverse effects occurred [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/35,41-43\" class=\"abstract_t\">35,41-43</a>]. In addition, serum assays (total n = 4 infants) found that risperidone and the active metabolite were not detected, except for one infant in which the metabolite was present at minimal concentrations [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/35,42,43\" class=\"abstract_t\">35,42,43</a>]. Consistent with these findings, a case report found that secretion of risperidone and the metabolite into breast milk was modest [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/44\" class=\"abstract_t\">44</a>]. The use of risperidone in breastfeeding women who are treated with a second-generation antipsychotic is consistent with guidance from the National Library of Medicine&rsquo;s <a href=\"http://toxnet.nlm.nih.gov/&amp;token=uFbFTjFpzLQOPfYhN9e/pY7DH5viCPnIbTllaDu+DrTYMoqo9S1gI8gS1H3WjssW&amp;TOPIC_ID=93451\" target=\"_blank\" class=\"external\">LactMed</a> (United States) database [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/15\" class=\"abstract_t\">15</a>]. In addition, a review of observational studies that examined secretion of risperidone into breast milk and adverse effects in infants concluded that risperidone is compatible with breastfeeding [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/7\" class=\"abstract_t\">7</a>].</p><p class=\"headingAnchor\" id=\"H86353781\"><span class=\"h3\">Ziprasidone</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>It is not clear if <a href=\"topic.htm?path=ziprasidone-drug-information\" class=\"drug drug_general\">ziprasidone</a> is compatible with breastfeeding due to the paucity of data [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/20,21,27\" class=\"abstract_t\">20,21,27</a>]. A single case report found that infant exposure to ziprasidone through breast milk resulted in no acute adverse effects [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/45\" class=\"abstract_t\">45</a>]. In another case report, ziprasidone breast milk concentrations were measured for 16 consecutive days; the drug was not detectable except on day 10, at which point the level was very low [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/46\" class=\"abstract_t\">46</a>].</p><p class=\"headingAnchor\" id=\"H86351587\"><span class=\"h1\">LITHIUM</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no clear consensus on the safety of <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> in breastfeeding women [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/47\" class=\"abstract_t\">47</a>]. Treatment with lithium versus other drugs thus needs to be considered on a case-by-case basis, and needs to account for patient values and preferences regarding risks such as relapse and infant exposure. As an example, a woman with bipolar disorder who has been well-controlled on lithium during pregnancy may not want to risk relapse by cross-tapering to a different medication following childbirth, when the risk for postpartum mood episodes is very high [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/6\" class=\"abstract_t\">6</a>].</p><p>Among women who are breastfeeding, we suggest limiting the use of <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> to those cases in which each of the following criteria are met [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/48\" class=\"abstract_t\">48</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patient is clinically stable and has participated in a discussion of the risks and benefits of using <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> while breastfeeding. (Clinically unstable patients who are hospitalized can pump their breast milk to maintain their supply.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pharmacotherapy consists of <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> monotherapy or lithium plus one or two other drugs.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Infant is healthy (eg, preterm babies may be more sensitive to medications, although data are limited).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patient and pediatrician can adhere to recommendations for monitoring the infant. (See <a href=\"#H29038627\" class=\"local\">'Monitoring'</a> above.)</p><p/><p>Some authorities think that <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> is reasonable for patients who have been successfully treated with it [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/10,49,50\" class=\"abstract_t\">10,49,50</a>], based upon evidence that nursing infants exposed to lithium generally do not suffer adverse events [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/21,51,52\" class=\"abstract_t\">21,51,52</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A prospective observational study of 10 mother-infant pairs found that growth and neurodevelopment was within normal limits [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/53\" class=\"abstract_t\">53</a>]. All 10 infants had normal thyroid-stimulating hormone (TSH), blood urea nitrogen (BUN), and creatinine levels at birth, but during the course of breastfeeding one infant developed a slightly elevated TSH (which normalized after <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> was stopped); two developed a transient, slightly elevated BUN; and one a transient, slightly elevated creatinine.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A retrospective study of nursing infants (n = 11) found that no adverse effects occurred [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/54\" class=\"abstract_t\">54</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A review of case reports (n = 5 infants) found that no adverse events occurred [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/49\" class=\"abstract_t\">49</a>].</p><p/><p>However, <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> is often not used in breastfeeding mothers. Treatment guidelines from the United Kingdom&rsquo;s National Institute for Health and Clinical Excellence discourage the use of lithium in lactating patients [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/6\" class=\"abstract_t\">6</a>], and some authorities maintain that lithium is contraindicated in the setting of lactation [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/13,55-57\" class=\"abstract_t\">13,55-57</a>]. Exposure to lithium through breast milk may be associated with adverse events:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>One prospective observational study of breastfeeding infants (n = 4) whose mothers took <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> during pregnancy and lactation found that two infants developed feeding difficulties, which resolved with breastfeeding education and support; one of the two infants also had mild hypotonia [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/9\" class=\"abstract_t\">9</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>One case report described an infant who was exposed to <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> through breast milk during the first postpartum week and suffered cyanosis, heart murmur, and T-wave inversions on an electrocardiogram, hypothermia, hypotonia, and lethargy [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/58\" class=\"abstract_t\">58</a>]. However, lithium and a diuretic were taken during the pregnancy, which may have at least partially accounted for the adverse events that occurred soon after delivery.</p><p/><p>Breast milk and infant serum concentrations are frequently substantial, with infant levels of 10 to 60 percent of maternal serum concentrations [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/47,52,59\" class=\"abstract_t\">47,52,59</a>]. <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">Lithium</a> can accumulate in newborns because kidney function is immature [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/49\" class=\"abstract_t\">49</a>]. In addition, infant serum levels may be less stable due to fluctuating hydration and intercurrent infections, which places infants at risk of lithium toxicity and necessitates invasive monitoring of infant levels [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/47\" class=\"abstract_t\">47</a>].</p><p class=\"headingAnchor\" id=\"H118012037\"><span class=\"h1\">STIMULANTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although theoretical concerns exist that exposure to stimulants via breast milk may adversely affect infant sleep, appetite, and growth [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/60\" class=\"abstract_t\">60</a>], observational studies suggest that some stimulants may be compatible with breastfeeding:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Small studies of women with attention deficit hyperactivity disorder or narcolepsy, who were prescribed amphetamine (n = 1) [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/61\" class=\"abstract_t\">61</a>], <a href=\"topic.htm?path=dextroamphetamine-drug-information\" class=\"drug drug_general\">dextroamphetamine</a> (n = 4) [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/62\" class=\"abstract_t\">62</a>], or <a href=\"topic.htm?path=methylphenidate-drug-information\" class=\"drug drug_general\">methylphenidate</a> (n = 3) [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/63-65\" class=\"abstract_t\">63-65</a>], found that their breastfeeding infants suffered no adverse effects.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In an older study of nursing infants (n = 103) who were exposed to <a href=\"topic.htm?path=dextroamphetamine-drug-information\" class=\"drug drug_general\">dextroamphetamine</a> that was prescribed for postpartum maternal depression, neonatal insomnia or stimulation did not occur [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/66\" class=\"abstract_t\">66</a>].</p><p/><p>In addition, stimulant drug concentration in breast milk and infant serum is often low [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/12,62-64\" class=\"abstract_t\">12,62-64</a>], but varies substantially [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/67\" class=\"abstract_t\">67</a>]. </p><p class=\"headingAnchor\" id=\"H118012023\"><span class=\"h1\">MEDICATIONS FOR SUBSTANCE USE DISORDERS</span></p><p class=\"headingAnchor\" id=\"H86351599\"><span class=\"h2\">Buprenorphine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=buprenorphine-drug-information\" class=\"drug drug_general\">Buprenorphine</a> may be compatible with breastfeeding. Multiple observational studies have found that the amount of buprenorphine and its metabolite that accumulates in breast milk is small and thus unlikely to negatively affect infants [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/68-70\" class=\"abstract_t\">68-70</a>]. As an example, a prospective study of breastfeeding women treated with buprenorphine (n = 7) found that no adverse affects occurred in the infants [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/71\" class=\"abstract_t\">71</a>]. Nevertheless, potential adverse effects that may occur include lethargy, respiratory difficulty, and poor weight gain [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/72\" class=\"abstract_t\">72</a>].</p><p>Prenatal exposure to <a href=\"topic.htm?path=buprenorphine-drug-information\" class=\"drug drug_general\">buprenorphine</a> often leads to the neonatal abstinence syndrome and the need for postnatal pharmacotherapy (eg, oral <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a>). The duration of pharmacotherapy may be shorter in breastfeeding infants (who are exposed to buprenorphine through breast milk due to ongoing maternal use of buprenorphine), compared with infants not breastfed [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/73\" class=\"abstract_t\">73</a>].</p><p class=\"headingAnchor\" id=\"H86351605\"><span class=\"h2\">Disulfiram</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>It is not clear if <a href=\"topic.htm?path=disulfiram-drug-information\" class=\"drug drug_general\">disulfiram</a> is compatible with breastfeeding because little information is available about its use in lactating women [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/15,72\" class=\"abstract_t\">15,72</a>].</p><p class=\"headingAnchor\" id=\"H86351611\"><span class=\"h2\">Methadone</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For opioid-dependent women who are engaged in substance abuse treatment and abstinent from illicit drug use, <a href=\"topic.htm?path=methadone-drug-information\" class=\"drug drug_general\">methadone</a> may be compatible with breastfeeding [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/68,74,75\" class=\"abstract_t\">68,74,75</a>]. Potential adverse effects in infants exposed to methadone through breast milk include lethargy, respiratory difficulty, and poor weight gain [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/72\" class=\"abstract_t\">72</a>]. However, studies have found that infant serum concentrations of methadone are typically low (&lt;3 percent of maternal concentrations) or undetectable [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/72,74\" class=\"abstract_t\">72,74</a>].</p><p>Among infants who are exposed prenatally to <a href=\"topic.htm?path=methadone-drug-information\" class=\"drug drug_general\">methadone</a>, breastfeeding may help prevent the neonatal abstinence syndrome. An observational study included infants (n = 78) who were exposed in utero to methadone and whose mothers continued methadone treatment following childbirth [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/73\" class=\"abstract_t\">73</a>]. The neonatal abstinence syndrome occurred in fewer infants who were breastfed than infants not breastfed (53 versus 80 percent). Among those infants who developed neonatal abstinence syndrome, the duration of pharmacotherapy (eg, oral <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a>) was shorter in breastfed infants than infants not breastfed (26 versus 39 days).</p><p>Breastfeeding mothers treated with <a href=\"topic.htm?path=methadone-drug-information\" class=\"drug drug_general\">methadone</a> should gradually wean their infants from breast milk; abrupt discontinuation of breastfeeding may cause the neonatal abstinence syndrome [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/72\" class=\"abstract_t\">72</a>].</p><p class=\"headingAnchor\" id=\"H86351617\"><span class=\"h2\">Naltrexone</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>It is not clear if <a href=\"topic.htm?path=naltrexone-drug-information\" class=\"drug drug_general\">naltrexone</a> is compatible with breastfeeding due to the paucity of data. In a case report of an opioid addict who was treated with naltrexone and breastfeeding, no acute adverse effects occurred [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/76\" class=\"abstract_t\">76</a>]. In addition, the infant serum concentration of naltrexone was not detectable, and the concentration of the primary metabolite was very low.</p><p class=\"headingAnchor\" id=\"H86351623\"><span class=\"h2\">Nicotine replacement therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nicotine replacement therapy (gum, lozenges, or patches) is compatible with breastfeeding, according to the 2013 report from the American Academy of Pediatrics Committee on Drugs [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/72\" class=\"abstract_t\">72</a>]. The suggested daily dose for these three products is less than the number of cigarettes typically smoked per day, based upon the assumption that one cigarette delivers approximately 1 mg of nicotine.</p><p>Shorter-acting gum or lozenges are preferable for lactating patients, but longer-acting patches are a reasonable alternative. A study of breastfeeding women who were smokers and treated with nicotine patches (n = 15) found that infant cognition and behavior were normal and that infant serum concentrations of nicotine were not detectable [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/77\" class=\"abstract_t\">77</a>].</p><p class=\"headingAnchor\" id=\"H86351629\"><span class=\"h2\">Varenicline</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Little information is available about the safety of <a href=\"topic.htm?path=varenicline-drug-information\" class=\"drug drug_general\">varenicline</a> in breastfeeding women [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/15,72\" class=\"abstract_t\">15,72</a>].</p><p class=\"headingAnchor\" id=\"H3603434982\"><span class=\"h1\">DRUG SAFETY INFORMATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Multiple resources provide information about the safety of medications in women who are breastfeeding [<a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/78\" class=\"abstract_t\">78</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>National Library of Medicine&rsquo;s <a href=\"http://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm&amp;token=uFbFTjFpzLQOPfYhN9e/pQnyw7Zq325jclNuEZrgvWE5qEDXC8BYslQiUWuTXChFpW6XZtKFqw8EFQSCTVAGmQ==&amp;TOPIC_ID=93451\" target=\"_blank\" class=\"external\">LactMed</a></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.urmc.rochester.edu/childrens-hospital/neonatology/lactation.aspx&amp;token=AU7Gp9NfqxZvKJcqfzHJfYszL2GPSPG770/6GhA6C9nI0pHpe7MuZS8KFPBEQPIXzRzErmTgKSPm8pNygQar1A52JqCu4m5/Imz6RU4uIOo=&amp;TOPIC_ID=93451\" target=\"_blank\" class=\"external\">The Breastfeeding and Human Lactation Study Center</a></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.motherisk.org/&amp;token=GAhe3OOzVjSUOiFPkwJclRwNYoCa0y3nhN5+zYy1m1y77hz7i193fFEsLz6U3Nvs&amp;TOPIC_ID=93451\" target=\"_blank\" class=\"external\">The Motherisk Program</a></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.breastfeedingnetwork.org.uk/&amp;token=wkK3meDdGl8H0MjoHsM/Rz91gFcg15sDqZXQOqdfr45XZ3k4U6vQ3b0jEK1jIP/WrwC1JCwUsNIWoeWxLU0oqw==&amp;TOPIC_ID=93451\" target=\"_blank\" class=\"external\">The Breastfeeding Network</a></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://reprotox.org/&amp;token=Ryuc2NABJGKCQZO0cGQLQ+lIiapLy0sf7zMh/rkID0g=&amp;TOPIC_ID=93451\" target=\"_blank\" class=\"external\">Reprotox</a></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://mothertobaby.org/&amp;token=cjWcuFd4xzPwN3syululi0BZIoY3uIDSoxeE/FYkZXAng4095mMxYKel1K7syBN0&amp;TOPIC_ID=93451\" target=\"_blank\" class=\"external\">MotherToBaby</a></p><p/><p class=\"headingAnchor\" id=\"H86351635\"><span class=\"h1\">EDUCATIONAL RESOURCES FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Educational resources for patients about breastfeeding are discussed separately. (See <a href=\"topic.htm?path=breastfeeding-parental-education-and-support#H7\" class=\"medical medical_review\">&quot;Breastfeeding: Parental education and support&quot;, section on 'Educational resources'</a>.)</p><p class=\"headingAnchor\" id=\"H751477256\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-depressive-disorders\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Depressive disorders&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=health-and-nutrition-for-women-who-breastfeed-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Health and nutrition for women who breastfeed (The Basics)&quot;</a> and <a href=\"topic.htm?path=reducing-the-costs-of-medicines-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Reducing the costs of medicines (The Basics)&quot;</a> and <a href=\"topic.htm?path=postpartum-depression-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Postpartum depression (The Basics)&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=maternal-health-and-nutrition-during-breastfeeding-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Maternal health and nutrition during breastfeeding (Beyond the Basics)&quot;</a> and <a href=\"topic.htm?path=reducing-the-costs-of-medicines-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Reducing the costs of medicines (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H86351647\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with postpartum mental disorders who require pharmacotherapy should generally not be discouraged from breastfeeding. Low-quality studies suggest that the benefits of breastfeeding typically outweigh the small risk posed by psychotropic medications that are used to treat postpartum mental disorders in lactating mothers. (See <a href=\"#H86350618\" class=\"local\">'Introduction'</a> above and <a href=\"topic.htm?path=safety-of-infant-exposure-to-antidepressants-and-benzodiazepines-through-breastfeeding#H2611892\" class=\"medical medical_review\">&quot;Safety of infant exposure to antidepressants and benzodiazepines through breastfeeding&quot;, section on 'General principles'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>All psychotropic medications are transferred to breast milk in varying amounts and thus are passed onto the nursing infant. Exposure can generally be decreased by choosing medications with shorter half-lives and greater protein binding. The drug should be started at the lowest effective dose and titrated slowly. Additional caution about exposure through breastfeeding is warranted for premature, low birthweight, or sick infants. If adverse events in infants are suspected, mothers should immediately suspend breastfeeding. (See <a href=\"topic.htm?path=safety-of-infant-exposure-to-antidepressants-and-benzodiazepines-through-breastfeeding#H2611892\" class=\"medical medical_review\">&quot;Safety of infant exposure to antidepressants and benzodiazepines through breastfeeding&quot;, section on 'General principles'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients who are successfully treated with psychotropic drugs during pregnancy should generally not change medications for the purpose of breastfeeding. In addition, breastfeeding patients who initiate pharmacotherapy should be treated with medications that were efficacious in the past. Polypharmacy should be avoided if possible. (See <a href=\"topic.htm?path=safety-of-infant-exposure-to-antidepressants-and-benzodiazepines-through-breastfeeding#H1336971\" class=\"medical medical_review\">&quot;Safety of infant exposure to antidepressants and benzodiazepines through breastfeeding&quot;, section on 'Choosing a drug'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Infants exposed to medications via breast milk should be assessed by pediatricians at baseline and subsequently monitored periodically for adverse events. Serum laboratory tests for infants should also be performed for all indices that can be affected by the medications that the mother is taking (<a href=\"image.htm?imageKey=PSYCH%2F93613\" class=\"graphic graphic_table graphicRef93613 \">table 1</a>). (See <a href=\"#H29038627\" class=\"local\">'Monitoring'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most of the evidence regarding the safety of anticonvulsants during lactation comes from patients with epilepsy. (See <a href=\"topic.htm?path=management-of-epilepsy-and-pregnancy#H15\" class=\"medical medical_review\">&quot;Management of epilepsy and pregnancy&quot;, section on 'Breast feeding'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">Haloperidol</a> and <a href=\"topic.htm?path=chlorpromazine-drug-information\" class=\"drug drug_general\">chlorpromazine</a> may be compatible with breastfeeding. (See <a href=\"#H86349450\" class=\"local\">'First-generation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">Olanzapine</a>, <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a>, and <a href=\"topic.htm?path=risperidone-drug-information\" class=\"drug drug_general\">risperidone</a> may be compatible with breastfeeding. By contrast, breastfeeding is typically discouraged in patients treated with <a href=\"topic.htm?path=clozapine-drug-information\" class=\"drug drug_general\">clozapine</a>. (See <a href=\"#H86349456\" class=\"local\">'Second-generation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There is no clear consensus on the safety and use of <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> in breastfeeding women. (See <a href=\"#H86351587\" class=\"local\">'Lithium'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=buprenorphine-drug-information\" class=\"drug drug_general\">Buprenorphine</a>, <a href=\"topic.htm?path=methadone-drug-information\" class=\"drug drug_general\">methadone</a>, and nicotine replacement therapy may be compatible with breastfeeding. (See <a href=\"#H118012023\" class=\"local\">'Medications for substance use disorders'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Multiple resources provide information about the safety of medications in women who are breastfeeding. (See <a href=\"#H3603434982\" class=\"local\">'Drug safety information'</a> above.) </p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/1\" class=\"nounderline abstract_t\">Hale, TW. Pharmacology Review: Drug Therapy and Breastfeeding: Antidepressants, Antipsychotics, Antimanics, and Sedatives. NeoReviews 2004; 5:e451.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/2\" class=\"nounderline abstract_t\">Berle J&Oslash;, Steen VM, Aamo TO, et al. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes. J Clin Psychiatry 2004; 65:1228.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/3\" class=\"nounderline abstract_t\">Lanza di Scalea T, Wisner KL. Antidepressant medication use during breastfeeding. Clin Obstet Gynecol 2009; 52:483.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/4\" class=\"nounderline abstract_t\">Weisskopf E, Fischer CJ, Bickle Graz M, et al. Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence. Expert Opin Drug Saf 2015; 14:413.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/5\" class=\"nounderline abstract_t\">Kim DR, Epperson CN, Weiss AR, Wisner KL. Pharmacotherapy of postpartum depression: an update. Expert Opin Pharmacother 2014; 15:1223.</a></li><li class=\"breakAll\">National Institute for Health and Care Excellence. Antenatal and postnatal mental health: clinical management and service guidance. NICE clinical guideline 192. December 2014. http://www.nice.org.uk/ (Accessed on April 19, 2015).</li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/7\" class=\"nounderline abstract_t\">Klinger G, Stahl B, Fusar-Poli P, Merlob P. Antipsychotic drugs and breastfeeding. Pediatr Endocrinol Rev 2013; 10:308.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/8\" class=\"nounderline abstract_t\">Stiegler A, Schaletzky R, Walter G, et al. Olanzapine treatment during pregnancy and breastfeeding: a chance for women with psychotic illness? Psychopharmacology (Berl) 2014; 231:3067.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/9\" class=\"nounderline abstract_t\">Bogen DL, Sit D, Genovese A, Wisner KL. Three cases of lithium exposure and exclusive breastfeeding. Arch Womens Ment Health 2012; 15:69.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/10\" class=\"nounderline abstract_t\">Stowe ZN. The use of mood stabilizers during breastfeeding. J Clin Psychiatry 2007; 68 Suppl 9:22.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/11\" class=\"nounderline abstract_t\">Llewellyn A, Stowe ZN, Strader JR Jr. The use of lithium and management of women with bipolar disorder during pregnancy and lactation. J Clin Psychiatry 1998; 59 Suppl 6:57.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/12\" class=\"nounderline abstract_t\">Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. Acta Psychiatr Scand Suppl 2015; :1.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/13\" class=\"nounderline abstract_t\">Fortinguerra F, Clavenna A, Bonati M. Psychotropic drug use during breastfeeding: a review of the evidence. Pediatrics 2009; 124:e547.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/14\" class=\"nounderline abstract_t\">McAllister-Williams RH, Baldwin DS, Cantwell R, et al. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. J Psychopharmacol 2017; 31:519.</a></li><li class=\"breakAll\">United States National Library of Medicine. Toxicology Data Network: Drugs and Lactation Database (LactMed). http://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm (Accessed on April 15, 2015).</li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/16\" class=\"nounderline abstract_t\">Yoshida K, Smith B, Craggs M, Kumar RC. Investigation of pharmacokinetics and of possible adverse effects in infants exposed to tricyclic antidepressants in breast-milk. J Affect Disord 1997; 43:225.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/17\" class=\"nounderline abstract_t\">Yoshida K, Smith B, Craggs M, Kumar R. Neuroleptic drugs in breast-milk: a study of pharmacokinetics and of possible adverse effects in breast-fed infants. Psychol Med 1998; 28:81.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/18\" class=\"nounderline abstract_t\">Whalley LJ, Blain PG, Prime JK. Haloperidol secreted in breast milk. Br Med J (Clin Res Ed) 1981; 282:1746.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/19\" class=\"nounderline abstract_t\">Mendhekar DN, Andrade C. Uneventful use of haloperidol and trihehexyphenidyl during three consecutive pregnancies. Arch Womens Ment Health 2011; 14:83.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/20\" class=\"nounderline abstract_t\">Uguz F. Second-Generation Antipsychotics During the Lactation Period: A Comparative Systematic Review on Infant Safety. J Clin Psychopharmacol 2016; 36:244.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/21\" class=\"nounderline abstract_t\">Pacchiarotti I, Le&oacute;n-Caballero J, Murru A, et al. Mood stabilizers and antipsychotics during breastfeeding: Focus on bipolar disorder. Eur Neuropsychopharmacol 2016; 26:1562.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/22\" class=\"nounderline abstract_t\">Lutz UC, Hiemke C, Wiatr G, et al. Aripiprazole in pregnancy and lactation: a case report. J Clin Psychopharmacol 2010; 30:204.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/23\" class=\"nounderline abstract_t\">Kobune F, Sakata H, Sugiura A. Marmoset lymphoblastoid cells as a sensitive host for isolation of measles virus. J Virol 1990; 64:700.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/24\" class=\"nounderline abstract_t\">Schlotterbeck P, Leube D, Kircher T, et al. Aripiprazole in human milk. Int J Neuropsychopharmacol 2007; 10:433.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/25\" class=\"nounderline abstract_t\">Barnas C, Bergant A, Hummer M, et al. Clozapine concentrations in maternal and fetal plasma, amniotic fluid, and breast milk. Am J Psychiatry 1994; 151:945.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/26\" class=\"nounderline abstract_t\">Gentile S. Infant safety with antipsychotic therapy in breast-feeding: a systematic review. J Clin Psychiatry 2008; 69:666.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/27\" class=\"nounderline abstract_t\">Kronenfeld N, Berlin M, Shaniv D, Berkovitch M. Use of Psychotropic Medications in Breastfeeding Women. Birth Defects Res 2017; 109:957.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/28\" class=\"nounderline abstract_t\">Gilad O, Merlob P, Stahl B, Klinger G. Outcome of infants exposed to olanzapine during breastfeeding. Breastfeed Med 2011; 6:55.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/29\" class=\"nounderline abstract_t\">Brunner E, Falk DM, Jones M, et al. Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. BMC Pharmacol Toxicol 2013; 14:38.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/30\" class=\"nounderline abstract_t\">Croke S, Buist A, Hackett LP, et al. Olanzapine excretion in human breast milk: estimation of infant exposure. Int J Neuropsychopharmacol 2002; 5:243.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/31\" class=\"nounderline abstract_t\">Gardiner SJ, Kristensen JH, Begg EJ, et al. Transfer of olanzapine into breast milk, calculation of infant drug dose, and effect on breast-fed infants. Am J Psychiatry 2003; 160:1428.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/32\" class=\"nounderline abstract_t\">Lutz UC, Wiatr G, Orlikowsky T, et al. Olanzapine treatment during breast feeding: a case report. Ther Drug Monit 2008; 30:399.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/33\" class=\"nounderline abstract_t\">Kirchheiner J, Bergh&ouml;fer A, Bolk-Weischedel D. Healthy outcome under olanzapine treatment in a pregnant woman. Pharmacopsychiatry 2000; 33:78.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/34\" class=\"nounderline abstract_t\">Whitworth A, Stuppaeck C, Yazdi K, et al. Olanzapine and breast-feeding: changes of plasma concentrations of olanzapine in a breast-fed infant over a period of 5 months. J Psychopharmacol 2010; 24:121.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/35\" class=\"nounderline abstract_t\">Ilett KF, Hackett LP, Kristensen JH, et al. Transfer of risperidone and 9-hydroxyrisperidone into human milk. Ann Pharmacother 2004; 38:273.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/36\" class=\"nounderline abstract_t\">Rampono J, Kristensen JH, Ilett KF, et al. Quetiapine and breast feeding. Ann Pharmacother 2007; 41:711.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/37\" class=\"nounderline abstract_t\">Misri S, Corral M, Wardrop AA, Kendrick K. Quetiapine augmentation in lactation: a series of case reports. J Clin Psychopharmacol 2006; 26:508.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/38\" class=\"nounderline abstract_t\">Lee A, Giesbrecht E, Dunn E, Ito S. Excretion of quetiapine in breast milk. Am J Psychiatry 2004; 161:1715.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/39\" class=\"nounderline abstract_t\">Yazdani-Brojeni P, Taguchi N, Garcia-Bournissen F, et al. Quetiapine in human milk and simulation-based assessment of infant exposure. Clin Pharmacol Ther 2010; 87:(Suppl. 1):S3.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/40\" class=\"nounderline abstract_t\">Var L, Ince I, Topuzoglu A, Yildiz A. Management of postpartum manic episode without cessation of breastfeeding: A longitudinal follow up of drug excretion into breast milk. Eur Neuropsychopharmacol 2013; 23 (Suppl 2):S382.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/41\" class=\"nounderline abstract_t\">Ratnayake T, Libretto SE. No complications with risperidone treatment before and throughout pregnancy and during the nursing period. J Clin Psychiatry 2002; 63:76.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/42\" class=\"nounderline abstract_t\">Aichhorn W, Stuppaeck C, Whitworth AB. Risperidone and breast-feeding. J Psychopharmacol 2005; 19:211.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/43\" class=\"nounderline abstract_t\">Weggelaar NM, Keijer WJ, Janssen PK. A case report of risperidone distribution and excretion into human milk: how to give good advice if you have not enough data available. J Clin Psychopharmacol 2011; 31:129.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/44\" class=\"nounderline abstract_t\">Hill RC, McIvor RJ, Wojnar-Horton RE, et al. Risperidone distribution and excretion into human milk: case report and estimated infant exposure during breast-feeding. J Clin Psychopharmacol 2000; 20:285.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/45\" class=\"nounderline abstract_t\">Werremeyer A. Ziprasidone and citalopram use in pregnancy and lactation in a woman with psychotic depression. Am J Psychiatry 2009; 166:1298.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/46\" class=\"nounderline abstract_t\">Schlotterbeck P, Saur R, Hiemke C, et al. Low concentration of ziprasidone in human milk: a case report. Int J Neuropsychopharmacol 2009; 12:437.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/47\" class=\"nounderline abstract_t\">Grandjean EM, Aubry JM. Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety. CNS Drugs 2009; 23:397.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/48\" class=\"nounderline abstract_t\">Sharma V, Doobay M, Baczynski C. Bipolar postpartum depression: An update and recommendations. J Affect Disord 2017; 219:105.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/49\" class=\"nounderline abstract_t\">Burt VK, Suri R, Altshuler L, et al. The use of psychotropic medications during breast-feeding. Am J Psychiatry 2001; 158:1001.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/50\" class=\"nounderline abstract_t\">Davanzo R, Copertino M, De Cunto A, et al. Antidepressant drugs and breastfeeding: a review of the literature. Breastfeed Med 2011; 6:89.</a></li><li class=\"breakAll\">Briggs GG, Freeman RK. Lithium. In: Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, Tenth Edition, Wolters Kluwer, Philadelphia 2015. p.809.</li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/52\" class=\"nounderline abstract_t\">Frew JR. Psychopharmacology of bipolar I disorder during lactation: a case report of the use of lithium and aripiprazole in a nursing mother. Arch Womens Ment Health 2015; 18:135.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/53\" class=\"nounderline abstract_t\">Viguera AC, Newport DJ, Ritchie J, et al. Lithium in breast milk and nursing infants: clinical implications. Am J Psychiatry 2007; 164:342.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/54\" class=\"nounderline abstract_t\">Moretti ME, Koren G, Verjee Z, Ito S. Monitoring lithium in breast milk: an individualized approach for breast-feeding mothers. Ther Drug Monit 2003; 25:364.</a></li><li class=\"breakAll\">Zappert LN, Rasgon NL. Managment of of bipolar disorders in women. In: Handbook of Diagnosis and Treatment of Bipolar Disorders, Ketter TA (Ed), American Psychiatric Publishing, Inc, Washington, DC 2010. p.425.</li><li class=\"breakAll\">Frey BN, Macritchie KA, Soares CN, Steiner M. Bipolar disoredr in women. In: Bipolar Disorder: Clinical and Neurobiological Foundations, Yatham LN, Maj M (Eds), Wiley-Blackwell, West Sussex, UK 2010. p.463.</li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/57\" class=\"nounderline abstract_t\">Eberhard-Gran M, Eskild A, Opjordsmoen S. Use of psychotropic medications in treating mood disorders during lactation : practical recommendations. CNS Drugs 2006; 20:187.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/58\" class=\"nounderline abstract_t\">Tunnessen WW Jr, Hertz CG. Toxic effects of lithium in newborn infants: a commentary. J Pediatr 1972; 81:804.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/59\" class=\"nounderline abstract_t\">Uguz F, Sharma V. Mood stabilizers during breastfeeding: a systematic review of the recent literature. Bipolar Disord 2016; 18:325.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/60\" class=\"nounderline abstract_t\">Freeman MP. ADHD and pregnancy. Am J Psychiatry 2014; 171:723.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/61\" class=\"nounderline abstract_t\">&Ouml;hman I, Wikner BN, Beck O, Sarman I. Narcolepsy Treated with Racemic Amphetamine during Pregnancy and Breastfeeding. J Hum Lact 2015; 31:374.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/62\" class=\"nounderline abstract_t\">Ilett KF, Hackett LP, Kristensen JH, Kohan R. Transfer of dexamphetamine into breast milk during treatment for attention deficit hyperactivity disorder. Br J Clin Pharmacol 2007; 63:371.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/63\" class=\"nounderline abstract_t\">Spigset O, Brede WR, Zahlsen K. Excretion of methylphenidate in breast milk. Am J Psychiatry 2007; 164:348.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/64\" class=\"nounderline abstract_t\">Hackett LP, Kristensen JH, Hale TW, et al. Methylphenidate and breast-feeding. Ann Pharmacother 2006; 40:1890.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/65\" class=\"nounderline abstract_t\">Bolea-Alamanac BM, Green A, Verma G, et al. Methylphenidate use in pregnancy and lactation: a systematic review of evidence. Br J Clin Pharmacol 2014; 77:96.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/66\" class=\"nounderline abstract_t\">Ayd FJ Jr. Excretion of psychotropic drugs in human breast milk. International Drug Therapy Newsletter 1973; VIII:33.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/67\" class=\"nounderline abstract_t\">Thorpy M, Zhao CG, Dauvilliers Y. Management of narcolepsy during pregnancy. Sleep Med 2013; 14:367.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/68\" class=\"nounderline abstract_t\">Academy of Breastfeeding Medicine Protocol Committee, Jansson LM. ABM clinical protocol #21: Guidelines for breastfeeding and the drug-dependent woman. Breastfeed Med 2009; 4:225.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/69\" class=\"nounderline abstract_t\">Ilett KF, Hackett LP, Gower S, et al. Estimated dose exposure of the neonate to buprenorphine and its metabolite norbuprenorphine via breastmilk during maternal buprenorphine substitution treatment. Breastfeed Med 2012; 7:269.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/70\" class=\"nounderline abstract_t\">Lindemalm S, Nydert P, Svensson JO, et al. Transfer of buprenorphine into breast milk and calculation of infant drug dose. J Hum Lact 2009; 25:199.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/71\" class=\"nounderline abstract_t\">Gower S, Bartu A, Ilett KF, et al. The wellbeing of infants exposed to buprenorphine via breast milk at 4 weeks of age. J Hum Lact 2014; 30:217.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/72\" class=\"nounderline abstract_t\">Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: An update on selected topics. Pediatrics 2013; 132:e796.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/73\" class=\"nounderline abstract_t\">Welle-Strand GK, Skurtveit S, Jansson LM, et al. Breastfeeding reduces the need for withdrawal treatment in opioid-exposed infants. Acta Paediatr 2013; 102:1060.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/74\" class=\"nounderline abstract_t\">Wojnar-Horton RE, Kristensen JH, Yapp P, et al. Methadone distribution and excretion into breast milk of clients in a methadone maintenance programme. Br J Clin Pharmacol 1997; 44:543.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/75\" class=\"nounderline abstract_t\">Bogen DL, Perel JM, Helsel JC, et al. Estimated infant exposure to enantiomer-specific methadone levels in breastmilk. Breastfeed Med 2011; 6:377.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/76\" class=\"nounderline abstract_t\">Chan CF, Page-Sharp M, Kristensen JH, et al. Transfer of naltrexone and its metabolite 6,beta-naltrexol into human milk. J Hum Lact 2004; 20:322.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/77\" class=\"nounderline abstract_t\">Ilett KF, Hale TW, Page-Sharp M, et al. Use of nicotine patches in breast-feeding mothers: transfer of nicotine and cotinine into human milk. Clin Pharmacol Ther 2003; 74:516.</a></li><li><a href=\"https://www.uptodate.com/contents/breastfeeding-infants-safety-of-exposure-to-antipsychotics-lithium-stimulants-and-medications-for-substance-use-disorders/abstract/78\" class=\"nounderline abstract_t\">Meltzer-Brody S, Jones I. Optimizing the treatment of mood disorders in the perinatal period. Dialogues Clin Neurosci 2015; 17:207.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 93451 Version 8.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H86351647\"><span>SUMMARY</span></a></li><li><a href=\"#H86350618\" id=\"outline-link-H86350618\">INTRODUCTION</a></li><li><a href=\"#H86353722\" id=\"outline-link-H86353722\">GENERAL PRINCIPLES</a><ul><li><a href=\"#H29038627\" id=\"outline-link-H29038627\">Monitoring</a></li></ul></li><li><a href=\"#H86350966\" id=\"outline-link-H86350966\">ANTICONVULSANTS</a></li><li><a href=\"#H86349444\" id=\"outline-link-H86349444\">ANTIPSYCHOTICS</a><ul><li><a href=\"#H86349450\" id=\"outline-link-H86349450\">First-generation</a><ul><li><a href=\"#H93853802\" id=\"outline-link-H93853802\">- Chlorpromazine</a></li><li><a href=\"#H1441316\" id=\"outline-link-H1441316\">- Haloperidol</a></li><li><a href=\"#H1441337\" id=\"outline-link-H1441337\">- Other drugs</a></li></ul></li><li><a href=\"#H86349456\" id=\"outline-link-H86349456\">Second-generation</a><ul><li><a href=\"#H86353740\" id=\"outline-link-H86353740\">- Aripiprazole</a></li><li><a href=\"#H39402073\" id=\"outline-link-H39402073\">- Asenapine</a></li><li><a href=\"#H86353753\" id=\"outline-link-H86353753\">- Clozapine</a></li><li><a href=\"#H39402100\" id=\"outline-link-H39402100\">- Lurasidone</a></li><li><a href=\"#H86353760\" id=\"outline-link-H86353760\">- Olanzapine</a></li><li><a href=\"#H536071189\" id=\"outline-link-H536071189\">- Paliperidone</a></li><li><a href=\"#H93853929\" id=\"outline-link-H93853929\">- Quetiapine</a></li><li><a href=\"#H86353767\" id=\"outline-link-H86353767\">- Risperidone</a></li><li><a href=\"#H86353781\" id=\"outline-link-H86353781\">- Ziprasidone</a></li></ul></li></ul></li><li><a href=\"#H86351587\" id=\"outline-link-H86351587\">LITHIUM</a></li><li><a href=\"#H118012037\" id=\"outline-link-H118012037\">STIMULANTS</a></li><li><a href=\"#H118012023\" id=\"outline-link-H118012023\">MEDICATIONS FOR SUBSTANCE USE DISORDERS</a><ul><li><a href=\"#H86351599\" id=\"outline-link-H86351599\">Buprenorphine</a></li><li><a href=\"#H86351605\" id=\"outline-link-H86351605\">Disulfiram</a></li><li><a href=\"#H86351611\" id=\"outline-link-H86351611\">Methadone</a></li><li><a href=\"#H86351617\" id=\"outline-link-H86351617\">Naltrexone</a></li><li><a href=\"#H86351623\" id=\"outline-link-H86351623\">Nicotine replacement therapy</a></li><li><a href=\"#H86351629\" id=\"outline-link-H86351629\">Varenicline</a></li></ul></li><li><a href=\"#H3603434982\" id=\"outline-link-H3603434982\">DRUG SAFETY INFORMATION</a></li><li><a href=\"#H86351635\" id=\"outline-link-H86351635\">EDUCATIONAL RESOURCES FOR PATIENTS</a></li><li><a href=\"#H751477256\" id=\"outline-link-H751477256\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H86351641\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H86351647\" id=\"outline-link-H86351647\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PSYCH/93451|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PSYCH/93613\" class=\"graphic graphic_table\">- Recommendations for infant monitoring</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-in-postpartum-women-treatment\" class=\"medical medical_review\">Bipolar disorder in postpartum women: Treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=breastfeeding-parental-education-and-support\" class=\"medical medical_review\">Breastfeeding: Parental education and support</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infant-benefits-of-breastfeeding\" class=\"medical medical_review\">Infant benefits of breastfeeding</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initiation-of-breastfeeding\" class=\"medical medical_review\">Initiation of breastfeeding</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-epilepsy-and-pregnancy\" class=\"medical medical_review\">Management of epilepsy and pregnancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=maternal-and-economic-benefits-of-breastfeeding\" class=\"medical medical_review\">Maternal and economic benefits of breastfeeding</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=obsessive-compulsive-disorder-in-pregnant-and-postpartum-women\" class=\"medical medical_review\">Obsessive-compulsive disorder in pregnant and postpartum women</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=health-and-nutrition-for-women-who-breastfeed-the-basics\" class=\"medical medical_basics\">Patient education: Health and nutrition for women who breastfeed (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=maternal-health-and-nutrition-during-breastfeeding-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Maternal health and nutrition during breastfeeding (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=postpartum-depression-the-basics\" class=\"medical medical_basics\">Patient education: Postpartum depression (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=reducing-the-costs-of-medicines-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Reducing the costs of medicines (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=reducing-the-costs-of-medicines-the-basics\" class=\"medical medical_basics\">Patient education: Reducing the costs of medicines (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=safety-of-infant-exposure-to-antidepressants-and-benzodiazepines-through-breastfeeding\" class=\"medical medical_review\">Safety of infant exposure to antidepressants and benzodiazepines through breastfeeding</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=severe-postpartum-unipolar-major-depression-treatment\" class=\"medical medical_review\">Severe postpartum unipolar major depression: Treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-depressive-disorders\" class=\"medical medical_society_guidelines\">Society guideline links: Depressive disorders</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-postpartum-psychosis\" class=\"medical medical_review\">Treatment of postpartum psychosis</a></li></ul></div></div>","javascript":null}